These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9515582)

  • 21. Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites.
    Sijwali PS; Kato K; Seydel KB; Gut J; Lehman J; Klemba M; Goldberg DE; Miller LH; Rosenthal PJ
    Proc Natl Acad Sci U S A; 2004 Jun; 101(23):8721-6. PubMed ID: 15166288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Partial purification and characterization of DNA topoisomerase II from Plasmodium falciparum.
    Chavalitshewinkoon P; Leelaphiwat S; Wilairat P
    Southeast Asian J Trop Med Public Health; 1994 Mar; 25(1):32-6. PubMed ID: 7825022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
    Deniskin R; Frame IJ; Sosa Y; Akabas MH
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Plasmodium falciparum proliferation in vitro by double-stranded RNA nanoparticle against malaria topoisomerase II.
    Attasart P; Boonma S; Sunintaboon P; Tanwilai D; Pothikasikorn J; Noonpakdee WT
    Exp Parasitol; 2016 May; 164():84-90. PubMed ID: 26953249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The H89 cAMP-dependent protein kinase inhibitor blocks Plasmodium falciparum development in infected erythrocytes.
    Syin C; Parzy D; Traincard F; Boccaccio I; Joshi MB; Lin DT; Yang XM; Assemat K; Doerig C; Langsley G
    Eur J Biochem; 2001 Sep; 268(18):4842-9. PubMed ID: 11559352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Replacement of the human topoisomerase linker domain with the plasmodial counterpart renders the enzyme camptothecin resistant.
    Arnò B; D'Annessa I; Tesauro C; Zuccaro L; Ottaviani A; Knudsen B; Fiorani P; Desideri A
    PLoS One; 2013; 8(7):e68404. PubMed ID: 23844196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of Plasmodium falciparum adenylyl cyclase-β and its role in erythrocytic stage parasites.
    Salazar E; Bank EM; Ramsey N; Hess KC; Deitsch KW; Levin LR; Buck J
    PLoS One; 2012; 7(6):e39769. PubMed ID: 22761895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical studies of membrane bound Plasmodium falciparum mitochondrial L-malate:quinone oxidoreductase, a potential drug target.
    Hartuti ED; Inaoka DK; Komatsuya K; Miyazaki Y; Miller RJ; Xinying W; Sadikin M; Prabandari EE; Waluyo D; Kuroda M; Amalia E; Matsuo Y; Nugroho NB; Saimoto H; Pramisandi A; Watanabe YI; Mori M; Shiomi K; Balogun EO; Shiba T; Harada S; Nozaki T; Kita K
    Biochim Biophys Acta Bioenerg; 2018 Mar; 1859(3):191-200. PubMed ID: 29269266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy.
    Reungprapavut S; Krungkrai SR; Krungkrai J
    J Enzyme Inhib Med Chem; 2004 Jun; 19(3):249-56. PubMed ID: 15499996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Farnesyltransferase Inhibitor R115777 on Mitochondria of Plasmodium falciparum.
    Ha YR; Hwang BG; Hong Y; Yang HW; Lee SJ
    Korean J Parasitol; 2015 Aug; 53(4):421-30. PubMed ID: 26323840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helicases - feasible antimalarial drug target for Plasmodium falciparum.
    Tuteja R
    FEBS J; 2007 Sep; 274(18):4699-704. PubMed ID: 17824956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on the mechanism of antimalarial action of a novel arylene bis(methylketone).
    Berger BJ; Dai WW; Cerami A; Ulrich P
    Biochem Pharmacol; 1997 Sep; 54(6):739-42. PubMed ID: 9310351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I.
    Das BB; Sen N; Roy A; Dasgupta SB; Ganguly A; Mohanta BC; Dinda B; Majumder HK
    Nucleic Acids Res; 2006; 34(4):1121-32. PubMed ID: 16488884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A class of potent antimalarials and their specific accumulation in infected erythrocytes.
    Wengelnik K; Vidal V; Ancelin ML; Cathiard AM; Morgat JL; Kocken CH; Calas M; Herrera S; Thomas AW; Vial HJ
    Science; 2002 Feb; 295(5558):1311-4. PubMed ID: 11847346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine.
    Sorensen M; Sehested M; Jensen PB
    Biochem Pharmacol; 1997 Aug; 54(3):373-80. PubMed ID: 9278096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic.
    Besterman JM
    Ann N Y Acad Sci; 1996 Dec; 803():202-9. PubMed ID: 8993513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks.
    Murren JR; Beidler DR; Cheng YC
    Ann N Y Acad Sci; 1996 Dec; 803():74-92. PubMed ID: 8993502
    [No Abstract]   [Full Text] [Related]  

  • 38. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
    Nallan L; Bauer KD; Bendale P; Rivas K; Yokoyama K; Hornéy CP; Pendyala PR; Floyd D; Lombardo LJ; Williams DK; Hamilton A; Sebti S; Windsor WT; Weber PC; Buckner FS; Chakrabarti D; Gelb MH; Van Voorhis WC
    J Med Chem; 2005 Jun; 48(11):3704-13. PubMed ID: 15916422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
    Bowman KJ; Newell DR; Calvert AH; Curtin NJ
    Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of DNA damage, inhibition of DNA synthesis, and suppression of c-myc expression by the topoisomerase I inhibitor, camptothecin, in MCF-7 human breast tumor cells.
    Jain PT; Fornari FA; Randolph JK; Orr MS; Gewirtz DA
    Biochem Pharmacol; 1998 Apr; 55(8):1263-9. PubMed ID: 9719482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.